Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Poya Ghorbani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2102-7168; OpenAlex author ID A5026406913. Sources: OpenAlex.

Their work

Papers
22 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
141
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 5 papers · 2026: 6 papers

Papers 22

  1. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  2. Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study. Co-author DOI 10.1016/j.pan.2025.12.008↗
  3. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  4. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  5. Multiple R1 margins are associated with shorter overall survival: national register-based study on pancreatic cancer. Last author DOI 10.1093/bjsopen/zrag155↗
  6. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  7. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  8. Performance of MRI-based surveillance for high-risk individuals for pancreatic cancer. Co-author DOI 10.1016/j.ejrad.2025.112275↗
  9. An injury-associated lobular microniche is associated with the classical tumor cell phenotype in pancreatic cancer. Co-author DOI 10.1038/s41467-025-63864-7↗
  10. Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocol. Co-author DOI 10.1186/s12893-025-02983-w↗
  11. Assessment of Outcomes by Intention-to-Treat Comparison for Locally Advanced Pancreatic Cancer: A Population-Derived Cohort Study. Last author DOI 10.1245/s10434-024-16291-9↗
  12. Consistency of a clinical decision support system with molecular tumour board recommendations for tumour sequencing-guided treatment of pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2024.100070↗
  13. Exhausted Tumor-infiltrating CD39+CD103+ CD8+ T Cells Unveil Potential for Increased Survival in Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0405↗
  14. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  15. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  16. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide re… Co-author DOI 10.1016/j.pan.2022.12.003↗
  17. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. Co-author DOI 10.1186/s12885-023-11141-5↗
  18. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal ad… Co-author DOI 10.1016/j.pan.2022.04.007↗
  19. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to … Co-author DOI 10.1016/j.suronc.2022.101735↗
  20. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2021.07.009↗
  21. Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled… Co-author DOI 10.1186/s13063-021-05248-y↗
  22. Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis. Co-author DOI 10.3390/jcm9113720↗

Closest collaborators

The 25 strongest of 141 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ernesto Sparrelid · 12 shared papers, 2021–2026 · strength 2.52
  2. Matthias J. Löhr · 8 shared papers, 2020–2026 · strength 1.58
  3. Marc G. Besselink · 8 shared papers, 2021–2026 · strength 1.27
  4. Marco Del Chiaro · 7 shared papers, 2021–2026 · strength 1.21
  5. Patrik Larsson · 5 shared papers, 2025–2026 · strength 1.21
  6. Carlos Fernández Moro · 5 shared papers, 2024–2026 · strength 1.20
  7. Thomas F. Stoop · 6 shared papers, 2024–2026 · strength 1.07
  8. Roeland F. de Wilde · 6 shared papers, 2024–2026 · strength 1.07
  9. Christopher Lee Wolfgang · 6 shared papers, 2024–2026 · strength 1.07
  10. Izaak Quintus Molenaar · 6 shared papers, 2021–2026 · strength 0.89
  11. Bas Groot Koerkamp · 5 shared papers, 2023–2026 · strength 0.88
  12. Ingmar Florin Rompen · 4 shared papers, 2026 · strength 0.76
  13. Richard David Schulick · 4 shared papers, 2026 · strength 0.76
  14. Marcus Holmberg · 4 shared papers, 2021–2023 · strength 0.73
  15. Maria Gustafsson Liljefors · 3 shared papers, 2024–2026 · strength 0.68
  16. Bobby Tingstedt · 3 shared papers, 2024–2026 · strength 0.66
  17. Miroslav Vujasinović · 3 shared papers, 2020–2026 · strength 0.66
  18. Freek D. Daams · 4 shared papers, 2021–2026 · strength 0.64
  19. Elena B. Rangelova · 3 shared papers, 2024–2026 · strength 0.59
  20. Hjalmar C. van Santvoort · 4 shared papers, 2021–2026 · strength 0.58
  21. Asif Halimi · 3 shared papers, 2025–2026 · strength 0.58
  22. Atsushi Oba · 3 shared papers, 2026 · strength 0.58
  23. Mark Joseph Truty · 3 shared papers, 2026 · strength 0.57
  24. Oskar Franklin · 3 shared papers, 2026 · strength 0.56
  25. Geert Kazemier M · 3 shared papers, 2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.